Results 41 to 50 of about 1,588,451 (244)
Light-Activated Azobenzene Peptide Inhibitor of the PD-1/PD-L1 Interaction [PDF]
Inhibiting the protein-protein interaction between programmed cell death 1 (PD-1) and its ligand programmed cell death ligand 1 (PD-L1) has become a focal point in immunotherapy for cancer treatments.
Deanne, Hayward +4 more
core +2 more sources
Oncolytic virotherapy is an emerging therapeutic approach based on replication-competent viruses able to selectively infect and destroy cancer cells, inducing the release of tumor-associated antigens and thereby recruiting immune cells with a subsequent ...
Maria Vitale (3528125) +11 more
core +1 more source
Smaller is better: nanobodies meet NMR
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley +1 more source
SQSTM1/p62-mediated PD-L1 biomolecular condensate formation promotes lung tumorigenesis
Introduction: Biomolecular condensates are membraneless organelles functionally involved in diverse processes, including cancer progression. Sequestosome-1 (SQSTM1)/p62 regulates liquid–liquid phase separation to drive biomolecular condensates, while ...
Yen-Cheng Lin +9 more
doaj +1 more source
BackgroundGalectin-3 (Gal-3) is a β-galactoside-binding lectin that is highly expressed within the tumor microenvironment of aggressive cancers and has been suggested to predict a poor response to immune checkpoint therapy with the anti-PD-1 monoclonal ...
James A. Roper +17 more
core +1 more source
Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley +1 more source
Background The expression of PD-L1 in the immune microenvironment can guide the application of immunosuppressants. In order to monitor the immune status of the body, repeated biopsies have to be taken.
Keyu Yuan +7 more
doaj +1 more source
Sex-dependent expression and release of PD-L1 by human endothelial cells
noneI checkpoint immunitari sono una classe di molecole che regola negativamente l’infiammazione, trasducendo segnali inibitori per le cellule del sistema immunitario.
MESTRINER, MAURO
core
Pioneering of Antibody-Assisted Structure-Based Drug Discovery for PD-L1
The principle of antibody-assisted drug discovery aims to use a diverse panel of single domain antibodies (VHH) to identify rare conformational states and/or novel allosteric sites that could modulate function, which may facilitate the discovery of new ...
Tara Kang-Pettinger (15905717)
core +1 more source
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source

